Albert Font

Durvalumab alone and durvalumab plus tremelimumab versus chemotherapy in previously untreated patients with unresectable, locally advanced or metastatic urothelial carcinoma (DANUBE): a randomised, open-label, multicentre, phase 3 trial

Michiel S. van der Heijden, Matthew D. Galsky, Yohann Loriot et al. · The Lancet Oncology · 2020 · 498 citations · Full text

Medicine, Oncology, Pharmacology +14

Randomized Phase II Study Evaluating Akt Blockade with Ipatasertib, in Combination with Abiraterone, in Patients with Metastatic Prostate Cancer with and without PTEN Loss

Johann S. de Bono, Ugo De Giorgi, Daniel Nava Rodrigues et al. · Clinical Cancer Research · 2018 · 310 citations

Medicine, Oncology, Pharmacology +15

Phase III Study Comparing a Reduced Dose of Cabazitaxel (20 mg/m²) and the Currently Approved Dose (25 mg/m²) in Postdocetaxel Patients With Metastatic Castration-Resistant Prostate Cancer—PROSELICA

Mario A. Eisenberger, Anne-Claire Hardy-Bessard, Choung‐Soo Kim et al. · Journal of Clinical Oncology · 2017 · 289 citations

Medicine, Oncology, Pharmacology +17

Androgen receptor gene status in plasma DNA associates with worse outcome on enzalutamide or abiraterone for castration-resistant prostate cancer: a multi-institution correlative biomarker study

Vincenza Conteduca, Daniel Wetterskog, Mansour T. A. Sharabiani et al. · Annals of Oncology · 2017 · 269 citations · Full text

Medicine, Oncology, Pharmacology +17

Kirsten ras mutations in patients with colorectal cancer: the ‘RASCAL II’ study

Jervoise Andreyev, A. R. Norman, David Cunningham et al. · British Journal of Cancer · 2001 · 204 citations · Full text

Medicine, Genetics, Oncology +13